Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human PDE3B Antibodies:
anti-Mouse (Murine) PDE3B Antibodies:
anti-Rat (Rattus) PDE3B Antibodies:
Go to our pre-filtered search.
Human Polyclonal PDE3B Primary Antibody for ELISA, WB - ABIN562146
Bazhin, Kahnert, Kimpfler, Schadendorf, Umansky: Distinct metabolism of cyclic adenosine monophosphate in regulatory and helper CD4+ T cells. in Molecular immunology 2010
Our results shed more light on phosphodiesterase 3A (show PDE3A Antibodies) activation and could be relevant to the treatment of severe hypertension in the general population.
Data indicate that genome-wide significant associations were found both at age 6 and 14 with single nucleotide polymorphisms (SNPs) on chromosome 11p15 in phosphodiesterase 3B, cGMP-inhibited protein PDE3B/cytochrome P-450 (show CYP Antibodies) CYP2R1 (show CYP2R1 Antibodies) genes.
PDE3B appears to be an important actor in regulation of energy metabolism and energy intake. Is inhibition of PDE3B a possible target for treatment of obesity or type 2 diabetes mellitus? [REVIEW]
PDE3B and the anti-lipolytic action of insulin (show INS Antibodies) may have a role in increased S-nitrosylation of adipose tissue in obesity
PDE3B is activated in response to agents relevant for beta-cell function and activation is linked to increased as well as decreased phosphorylation of the enzyme
PDE3B and EPAC1 (show RAPGEF3 Antibodies) bind directly through protein-protein interactions
Data suggest that five novel genes, LUM (show LUM Antibodies), PDE3B, PDGF-C (show PDGFC Antibodies), NRG1 (show NRG1 Antibodies) and PKD2 (show PKD2 Antibodies), have great potential for predicting the efficacy of cisplatin-based chemotherapy against OSCC.
Inhibition of PDE3B augments PDE4 (show PDE4A Antibodies) inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia
Results explain the dual cyclic AMP (show APRT Antibodies)/cyclic GMP (show NT5C2 Antibodies) binding capabilities of phosphodiesterase 3B and provide the molecular basis for inhibitor specificity.
p87PIKAP (show PIK3R6 Antibodies) is a novel regulatory subunit of phosphoinositide 3-kinase gamma that is highly expressed in heart and interacts with PDE3B [p87PIKAP (show PIK3R6 Antibodies)]
Study concludes that CUGBP1 (show CELF1 Antibodies) is a critical regulator of insulin (show INS Antibodies) secretion via activating PDE3B.
Insulin (show INS Antibodies) induction of hypothalamic phosphodiesterase 3B activity and the reversal of the anorectic and body weight-reducing effects and stimulatory effect of insulin (show INS Antibodies) on hypothalamic proopiomelanocortin (show POMC Antibodies) gene expression by cilostamide suggest that activation of phosphodiesterase 3B is a novel mechanism of insulin (show INS Antibodies) signaling in the hypothalamus.
These results suggest the possibility for a direct role for the PDE3B pathway in mediating leptin (show LEP Antibodies) action in the hypothalamus.
Suggest that by reducing production of cAMP in adipocytes, PDE3B, IKKepsilon (show IKBKE Antibodies) and TBK1 (show TBK1 Antibodies) may contribute to the repression of energy expenditure during obesity.
Lack of PDE3B in brown adipocytes impairs the action of insulin (show INS Antibodies) on lipolysis.
these findings indicate that PDE3B deletion confers cardioprotective effects because of cAMP/PKA-induced preconditioning, which is associated with the accumulation of proteins with cardioprotective function in ICEFs.
Data suggest that Pde3b is involved in regulation of adipogenesis of adult stem cells into white adipocytes versus brown adipocytes; knockout mice lacking Pde3b form epididymal white adipose tissue with characteristics of brown adipose tissue.
The variation of PDE3B-expression in the brain might play a crucial pathophysiological role, and regulation of PDE3B production might protect against ischemic brain damage.
Calcineurin regulates degradation of phosphodiesterase 3B, in addition to phosphodiesterase 4D (show PDE4D Antibodies).
The PDE3B pathway has a direct role in mediating leptin (show LEP Antibodies) signaling in proopiomelanocortin (show POMC Antibodies) and neuropeptide Y (show NPY Antibodies) neurons, via a potential mechanism of leptin (show LEP Antibodies) signaling in the hypothalamus.
catalyzes the hydrolysis of cAMP and cGMP; regulates insulin secretory processes
phosphodiesterase 3B, cGMP-inhibited
, cGMP-inhibited 3',5'-cyclic phosphodiesterase B-like
, CGI-PDE B
, cGMP-inhibited 3',5'-cyclic phosphodiesterase B
, cyclic GMP-inhibited phosphodiesterase B
, cyclic nucleotide phosphodiesterase
, phosphodiesterase 3B cGMP inhibited